Drug developer PharmaEngine Inc (智擎生技) said its French partner Nanobiotix SA has received European market approval for PEP503 (NBTXR3), enabling commercialization of the nanoparticle radio-enhancer in the EU for the treatment of locally advanced soft-tissue sarcoma.
PEP503 would be marketed in the 27 EU countries under the brand name Hensify, PharmaEngine said in a filing with the Taiwan Stock Exchange on Saturday.
PharmaEngine in August 2012 acquired the exclusive rights from Nanobiotix to develop and commercialize PEP503 in the Asia-Pacific region.
PharmaEngine might be able to license the treatment to other companies in the region in the near term, the Chinese-language Commercial Times reported yesterday, adding that royalty revenue from sales could start from US$200 million.
PEP503 is a nanoparticle formulation of crystalline hafnium oxide that was designed to enhance the efficacy of radiotherapy for cancer treatment, the company said.
In addition to the treatment of soft-tissue sarcoma, PEP503 is being evaluated for other cancer types, such as head-and-neck cancer, liver cancer, rectal cancer and prostate cancer, PharmaEngine said.
In the US, the treatment has gained approval for a clinical trial in combination with anti-PD-1 immunotherapies for patients of non-small-cell lung cancer and head-and-neck cancer, the company said.
PharmaEngine reported cumulative revenue of NT$61.04 million (US$1.98 million) for the first two months of the year, up 96.29 percent from NT$31.1 million the previous year, a company regulatory filing showed.
The surge in revenue was mainly due to contributions from its pancreatic cancer drug, Onivyde, which has received reimbursements of NT$26,400 per vial from the National Health Insurance Administration since August last year.
The company posted net profit of NT$129.36 million for last year, or NT$0.88 in earnings per share, compared with the year-earlier level of NT$387.06 million, or NT$2.62 per share.
More than 20,000 employees at Apple Inc supplier Foxconn Technology Group’s (富士康) huge Chinese plant, mostly new hires not yet working on production lines, have left, a Foxconn source familiar with the matter said yesterday. The departures from the world’s largest iPhone factory dealt a fresh blow to the Taiwanese company, which has been grappling with strict COVID-19 restrictions that have fueled worker discontent and disrupted production ahead of Christmas and January’s Lunar New Year holiday. Concerns are mounting over Apple’s ability to deliver products for the busy holiday period as the worker unrest lingers at the Zhengzhou plant, which produces the
FACTORY TUMULT: The departure of new workers impact production less than the quarantines imposed on existing employees, a worker at China’s ‘iPhone city’ said Turmoil at Apple Inc’s key manufacturing hub in Zhengzhou is likely to result in a production shortfall of almost 6 million iPhone Pro units this year, a person familiar with assembly operations said. The situation remains fluid at the plant and the estimate of lost production could change, the person said, asking not to be named discussing private information. Much depends on how quickly Hon Hai Precision Industry Co (鴻海精密), the Taiwanese company that operates the facility, can get people back to assembly lines after violent protests against COVID-19 restrictions. If lockdowns continue in the weeks ahead, production could be set further
’INHERENT VULNERABILITIES’: The country has been working with the US to build its own lithium and rare earth mines in a bid to curb China’s dominance in the market Australia is vowing more assertive scrutiny of foreign investments in key commodities tied to electric vehicles and clean energy, in a potential warning to China which dominates the market. Australian Treasurer Jim Chalmers has asked the country’s Treasury to work with the Australian Foreign Investment Review Board and other stakeholders to undertake a review of foreign investment in sectors such as lithium and rare earths, he told a conference in Sydney yesterday. “We’ll need to be more assertive about encouraging investment that clearly aligns with our national interest in the longer term,” Chalmers said. Although Chalmers did not directly identify China investment as
Alibaba Group Holding Ltd (阿里巴巴) founder Jack Ma (馬雲) has been living in Tokyo for almost six months after disappearing from public view following China’s crackdown on the tech sector, the Financial Times reported yesterday, citing multiple unnamed sources. The billionaire has kept a low profile since the crackdown, which has included Chinese regulators scrapping the initial public offering of Ma’s Ant Group Co (螞蟻集團) and issuing Alibaba with record fines. However, the Times said he has spent much of the past six months with his family in Tokyo and other parts of Japan, along with visits to the US and Israel. The